



Worldwide contacts for additional information

World Headquarters

Jared Hahn
Manager, Drug Delivery/Pharmaceuticals
Technology Catalysts International Corporation
605 Park Avenue
Falls Church, VA 22046, U.S.A.
Direct Line: (703) 531-0254
Fax: (703) 237-0042
E-mail: jhahn@technology-catalysts.com
Internet: www.technology-catalysts.com

South America

Carlos A. Massone, M.D.
President
Qualia S.A.
Jeronimo Salguero 2533, Piso 12 "A"
1425, Buenos Aires, Argentina
Telephone: 54 11 4807 3433
Facsimile: 54 11 4807 2933
E-mail: carlos.massone@qualia.com.ar
Internet: www.qualia.com.ar

Europe

Graham L. Crawford, MSc
Managing Director
Technology Catalysts International UK
Blacksmiths
Clifton Road
Newton Blossomville
Bedford MK43 8AS, UK
Telephone: 44 1234 881583
Facsimile: 44 1234 881027
E-mail: gcrawford@technology-catalysts.com

Gerhard Wallenwein, Ph.D.
Managing Director
Laves Chemie Consulting
Koenigsteiner Strasse 80
D-65812 Bad Soden, Germany
Telephone: 49 6196 62057
Facsimile: 49 6196 27837
E-mail: laveschemie@t-online.de
Internet: www.laveschemie.de

Jana Kuhnlova
Executive Managing Director
INVENTIA s.r.o.
Politických veznu 7
110 00 Praha 1, Czech Republic
Telephone: 420 2 2224 7484
Facsimile: 420 2 2421 8645
E-mail: kuhnlova@inventia.cz
Internet: www.inventia.cz

Jiri Krepelka, Ph.D.
General Manager
TCI Generics Europe
Politických veznu 7
110 00 Praha 1, Czech Republic
Telephone: 420 2 2224 7484
Facsimile: 420 2 2421 8645
E-mail: jkrepelka@technology-catalysts.com

Asia

Ken-ichi Itoh
President, TCJ Japan
2-46-4, Utsukushigaoka
Aoba-ku, Yokohama 225-0002, Japan
Telephone: 81 45 902 5304
Facsimile: 81 45 902 5476
E-mail: kenitoh@air.ocn.ne.jp

Mitsuhisa Tamura
Senior Research Associate
Sumika Technical Information Service Inc.
18 Fl., Tokyo Sumitomo Twin Bldg. (East)
27-1, Shinkawa 2-chome
Chuo-ku, Tokyo 104-0033, Japan
Telephone: 81 3 5543 5875
Facsimile: 81 3 5543 5945
E-mail: tamuram2@sc.sumitomo-chem.co.jp
Internet: www.stis.co.jp

G.R.S. Raghavan
General Manager
TCI India
97 Jolly Maker Chambers II
Nariman Point
Mumbai 400 021, India
Telephone: 91 22 5633 2727
Facsimile: 91 22 5633 2728
E-mail: grsraghavan@technology-catalysts.com

R.K. Gupta
Managing Director
Industrial Development Services Limited
M-1 Kanchenjunga
18 Barakhamba Road
New Delhi 110 001, India
Telephone: 91 11 2 331 2287, 2 331 4714
Facsimile: 91 11 2 373 8227
E-mail: ids@del2.vsnl.net.in
Website: www.idsindia.org

Yaping Shen, Ph.D.
Senior Director, Business Development
Xi'an Libang Pharmaceutical Co., Ltd.
C/7, Chuangye Tower, Xi'an High-Tech Zone
Xi'an, Shaanxi 710075, China
Telephone: 86 29 88315776, (604) 821-1141
Facsimile: 86 29 88323883, (604) 821-1175
E-mail: yshen@technology-catalysts.com

Visit TCI's website at:
www.technology-catalysts.com

Strategies for Bioavailability Enhancement of Poorly Soluble and Poorly Permeable Drugs

S I X T H E D I T I O N

Technology and Business Review

About Technology Catalysts International

Technology Catalysts International (TCI) was founded in 1979 to provide consulting services that satisfy the licensing and business research needs of the pharmaceutical and chemical industries. We specialize in technology licensing, technology assessment, and technology portfolio management. The firm is headquartered in Falls Church, Virginia, a suburb of Washington, D.C. Our global network includes offices in the United Kingdom, Germany, the Czech Republic, Argentina, India, China, and Japan.

Our research staff is composed of professionals with backgrounds in a variety of technical disciplines and additional expertise in international marketing, licensing, finance, and business development. The breadth of our experience assures clients of high quality, actionable information and complete coverage on topics of interest.

TCI's core consulting services are based on continuous monitoring of global technology developments. We provide consulting and technology transfer services to leading product developers and manufacturers in North and South America, Europe, and Asia. Our client base consists of small, medium, and large corporations.

For more information on our services and capabilities, please visit TCI's website at:

www.technology-catalysts.com

The Report

Technology Catalysts International has developed *Strategies for Bioavailability Enhancement of Poorly Soluble and Poorly Permeable Drugs*, a substantially updated Sixth Edition to the former *Poorly Soluble or Poorly Permeable Drugs* report series. After extensive analysis of the current pharmaceutical market, TCI provides this new edition with numerous opportunities for enhancing the bioavailability of BCS Class IV drug candidates with novel drug delivery technologies. This comprehensive report presents an inside view for companies interested in understanding or participating in this considerable market.

The Sixth Edition is unique in three significant ways: it clarifies the often vague terms and concepts associated with poorly soluble and poorly permeable drugs; it offers a vast listing of BCS Class IV drugs and drug properties; and finally, it discloses tried-and-true strategies that have yielded highly profitable products, including both brand and generic reformulations. This report dispenses unparalleled information on the BCS Class IV market, products, and technologies.

The report includes an in-depth introduction to bioavailability enhancement terminology, insightful market analysis of over 250 reviewed BCS Class IV drugs, numerous strategies and licensing opportunities for business development, straightforward scientific explanations, and over 185 novel drug delivery technologies applicable to poorly bioavailable drugs. Each drug has confirmed solubility and bioavailability properties, market status, pertinent technology, and pipeline records. Each technology profile contains: technology description, technology applications, technology offer (business opportunity), stage of development, patents/publications, competitive advantage, company summary, and complete contact information.

New to the Sixth Edition:

- Emphasis on BCS Class IV drugs
- Over 200 additional drug candidates verified as business opportunities
- Over 75 BCS Class IV pipeline drugs tracked
- Market strategies involving both brand and generic drugs
- Definitions of complex concepts
- Over 65 new drug delivery technologies added
- Additional technology sections that include: microparticles, solid emulsions, and covalent conjugation
- Updated market analysis

Key Information and Analysis Presented in the Report:

Introduction

- Definitions of Various Technology Terms and Concepts

Market Analysis

- Comparative Overview of Current Market with Updated Sales

Poorly Soluble and Poorly Permeable Drug Candidates

- Strategies for Involvement
- Government Regulatory Procedures
- Drugs Organized as Follows:
 - Marketed or Not Marketed*
 - Brand or Generic*
 - With or without Drug Delivery Technologies*
 - With or without Pipelines*
 - IV, Oral, or Other Formulations*
- Indications Include:
 - Anti-Infection*
 - Arthritis*
 - Central Nervous System*
 - Endocrinology*
 - Gastrointestinal*
 - Genito-Urinary*
 - Immunosuppression*
 - Oncology*
 - Pain*
 - Other*

Science of Solubility, Permeability, and Bioavailability

- Historical Progression of Bioavailability Enhancement
- Improving Solubility
- Improving Permeability

Technology Profiles (Licensing Opportunities)

- Nanoparticles (22 Technologies)
- Microparticles (32 Technologies)
- Micelles (16 Technologies)
- Liposomes (19 Technologies)
- Liquid Emulsions (27 Technologies)
- Solid Emulsions (10 Technologies)
- Permeation (24 Technologies)
- Conjugation (11 Technologies)
- Complexation (14 Technologies)
- Dispersion (47 Technologies)

Strategies for Bioavailability Enhancement of Poorly Soluble and Poorly Permeable Drugs

Order Form

First Copy (PDF or Paper)\$5,950

Extra Copies (Either Format)\$500

Note: All prices are U.S. dollars

Total Amount Due: _____

We agree to limit the circulation of any of this report to employees of our corporation or subsidiaries and joint ventures in which our corporation holds at least a 50 percent interest.

Upon receipt of this signed purchase agreement, Technology Catalysts International will invoice our corporation for the purchase amount, payable upon request.

Shipping/Purchase Information

Name _____

Title _____

Company _____

Address _____

Telephone _____

E-mail _____

Facsimile _____

Signature _____

Date _____

Send invoice to the address above

Check enclosed (Made payable to Technology Catalysts International)

Wire transfer (Please contact TCI directly for account information)

Credit Card (MC Visa Amex)

Card number _____

Expiration date _____ Security code (3 or 4 digits) _____

E-mail, Mail, fax, or phone orders to:

Jared Hahn

Manager, Drug Delivery/Pharmaceuticals

Technology Catalysts International Corporation

605 Park Avenue, Falls Church, VA 22046, U.S.A.

Telephone: (703) 531-0254

Facsimile: (703) 237-0042

E-mail: jhahn@technology-catalysts.com